Electronic Equipment, Instruments and Components
Company Overview of BiOptix Inc.
BiOptix Inc., an analytical instrumentation company, develops an array-based bio molecule detection systems and molecular interaction analysis instruments. The company’s products pipeline includes cell array biodetector systems, and biochip and optical cartridges; and pre-production small footprint and single cell biodetector systems. Its products are used to detect various molecules and micro organisms, including micro RNA, nucleic acids, proteins and antibodies, bacteria, viruses, carbohydrates, lipids, and low molecular weight drugs. The company serves clinical biomarkers and diagnostics, personalized medicine, infectious disease, drug discovery, biopharma and low molecular drug developme...
1775 38th Street
Boulder, CO 80301
Founded in 2003
Key Executives for BiOptix Inc.
Chief Executive Officer, President, and Member of Board of Directors
Co-Founder and Director of Research and Development
Vice President of Chemistry & Biochemistry
Compensation as of Fiscal Year 2016.
BiOptix Inc. Key Developments
BiOptix Announces Partnership with XTAL BioStructures
Sep 22 15
BiOptix announced XTAL BioStructures Inc. is adding the BiOptix 404pi to its suite of biophysical tools. XTAL BioStructures is a contract research organization that provides drug discovery and intellectual property development services to the pharmaceutical and biotechnology industries, including high quality protein production, biophysical characterization, X-ray crystallography and with a focus on affinity-based screening techniques. XTAL is now able to offer customers access to BiOptix’s patented enhanced surface plasmon resonance (e-SPR) technology, which delivers high sensitivity (100 Da) and higher throughput by combining proprietary technology with an advanced, multi-injector fluidics system.
BiOptix Announces Simulject™ Application
Aug 6 15
BiOptix announced their Simulject Application, a tool which allows researchers to inject two different concentrations of an analyte simultaneously on a BiOptix 404pi without the need for regeneration. The Simulject Application is enabled by the unique flow cell architecture within the biosensor. Two independent flow paths, each containing a reference and experimental flow cell, allow two different concentrations of analyte to be injected simultaneously, resulting in the kinetics and KD for an interaction in one injection cycle. The application is critical for molecular systems in which surface regeneration is challenging or impossible to find, thus saving researchers time and money. This technology adds another key feature to the BiOptix 404pi, which utilizes patented phase-based SPR technology, delivering high sensitivity (100 Da) and higher throughput without the high price tag. The 404pi utilizes 4 parallel channels allowing simultaneous characterization of 4 samples, and uses 96 well plates. Additional Features of the BiOptix 404pi include: phase-based SPR for high sensitivity; 4 injector /4 flow cell design for higher throughput; advanced automated fluidic system for fast kinetic measurements; multiple surface chemistries; compatible with industry standard Scrubber 2 software; and cost-effective and simple to operate.
BiOptix Appoints Scott Klakamp as Vice President of Chemistry and Biochemistry
Jan 22 15
BiOptix announced the appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry. Scott joins the company after previous scientific leadership positions at Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of his nearly 20 year career in therapeutics discovery and development.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 13, 2015